HONASA · NSE
Not in active coverage. Cited reporting has mentioned Honasa Consumer, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Honasa Consumer has called off its proposed acquisition of a 58 per cent stake in nutraceuticals company Fluence Pharma, citing non-fulfilment of closing conditions under the share purchase agreement.
New-age consumer and logistics firms managed cost increases during the April-June quarter. Strong sales growth and selective price hikes helped limit margin impacts for many companies. Honasa Consumer's gross margin declined slightly, while Wakefit saw an increase due to price adjustments.…
Honasa Consumer's Q1FY27 PAT surged 116.5% YoY to ₹90 crore, revenue grew 27% to ₹756 crore, and EBITDA jumped 140.7% to ₹110 crore.
This page lists where cited reporting has mentioned Honasa Consumer. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.